Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial w/ open-label extension (Apeldoorn et al, 2024) adds to previous ketamine findings

Escrito por Michael DeMarco

https://ketaminetherapypalmsprings.com/ketamine-research-1/oral-esketamine-in-patients-with-treatment-resistant-depression-a-double-blind-randomized-placebo-controlled-trial-w-open-label-extension-apeldoorn-et-al-2024-builds-adds-to-ketamine-findings

Michael DeMarco

Psychedelic therapist, clinical sexologist, and Founding Fellow of Psychedelic Institute of Mental Health and Family Therapy / Consultor en Medicina Psicodélica, sexólogo clínico y miembro fundador del Instituto Psicodélico SAS

https://psychedelicmentalhealth.net/michael-demarco-therapist
Anterior

American Journal of Nursing recommends Cognitive Behavioral Therapy Training for Treatment Resistant Schizophrenia (2022)
Siguiente

Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study (Aday, et al, 2024)